Citigroup Inc. Purchases 7,670 Shares of IDEXX Laboratories, Inc. $IDXX

Citigroup Inc. grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,452 shares of the company’s stock after acquiring an additional 7,670 shares during the period. Citigroup Inc.’s holdings in IDEXX Laboratories were worth $92,289,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after purchasing an additional 86,040 shares during the period. Geode Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after buying an additional 54,402 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after buying an additional 605,290 shares during the period. Principal Financial Group Inc. increased its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after acquiring an additional 187,967 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after acquiring an additional 326,348 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the transaction, the director owned 648 shares of the company’s stock, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 18,180 shares of company stock worth $11,626,996 over the last quarter. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $635.66 on Monday. The company has a market capitalization of $50.76 billion, a P/E ratio of 48.64, a P/E/G ratio of 3.87 and a beta of 1.67. The business has a fifty day simple moving average of $677.74 and a two-hundred day simple moving average of $669.32. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the company earned $2.53 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of recent research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a report on Tuesday, November 4th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Piper Sandler dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, BTIG Research lowered their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $783.33.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.